SynthesisBMC cancer2022
Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Heng Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it